SkinTwo labels compared
Isotretinoin vs tretinoin
Isotretinoin and tretinoin are both retinoids and both approved for acne, which is where the similarity stops. One is a capsule taken for a fixed course, the other a gel applied to the skin. Their labels do not describe the same patient, and they do not carry the same warnings.
Isotretinoin capsules
- Ingredient
- Isotretinoin
- Approved for
- Severe nodular acnecovers skin
- Supply
- Prescription
- Boxed warning
- WARNING: EMBRYO-FETAL TOXICITY
- Pharmacy cost
- $38.05 per tablet, capsule or pen, brandwhat pharmacies pay to buy it, not the price at the counter
Retin-A Micro
- Ingredient
- Tretinoin
- Approved for
- Acne vulgariscovers skin
- Supply
- Prescription
- Boxed warning
- None
- Pharmacy cost
- $1.02 per gram, genericwhat pharmacies pay to buy it, not the price at the counter
Side by side, straight from the labels
Generated from the two source labels, not typed out by hand, so it cannot drift from what the regulator approved. Rows where both labels say exactly the same thing are marked.
| Label section | Isotretinoin capsulesIsotretinoin | Retin-A MicroTretinoin |
|---|---|---|
| Active ingredient | Isotretinoin capsulesIsotretinoinOral retinoid | Retin-A MicroTretinoinTopical retinoid |
| Approved for | Isotretinoin capsulesSevere nodular acne | Retin-A MicroAcne vulgaris |
| Supplysame in both | Isotretinoin capsulesPrescription | Retin-A MicroPrescription |
| What pharmacies payAcquisition cost, not retail | Isotretinoin capsules$38.05 per tablet, capsule or pen, brand | Retin-A Micro$1.02 per gram, generic |
| Boxed warning | Isotretinoin capsulesWARNING: EMBRYO-FETAL TOXICITY | Retin-A MicroNone |
| What the FDA approved it for | Isotretinoin capsules
| Retin-A Micro
|
| Forms and strengths | Isotretinoin capsules
| Retin-A Micro
|
| How the label says it is taken | Isotretinoin capsules
| Retin-A Micro
|
| Most common adverse reactions | Isotretinoin capsules
| Retin-A Micro
|
| Warnings and precautions | Isotretinoin capsules
| Retin-A Micro
|
| Contraindications | Isotretinoin capsules
| Retin-A Micro
|
| Drug interactions | Isotretinoin capsules
| Retin-A Micro- |
| Label version | Isotretinoin capsules13 February 2026 | Retin-A Micro1 September 2025 |
The approved severities are not the same
The Retin-A Micro label covers the topical treatment of acne vulgaris in adults and pediatric patients 12 years of age and older. The isotretinoin label is narrower: severe recalcitrant nodular acne in non-pregnant patients 12 years and older with multiple inflammatory nodules.
The isotretinoin label goes further and states why it is written that way. Because of the significant adverse reactions associated with its use, it says, isotretinoin is reserved for patients with severe nodular acne who are unresponsive to conventional therapy. That sentence is a restriction, not a description, and it has no counterpart in the topical label.
One is a course, the other is an application
Isotretinoin is dosed by body weight in two divided doses daily for a set number of weeks, and its label states that once daily dosing is not recommended. Retin-A Micro is applied as a thin layer to the affected area once a day, and its label states that it is for topical use only, not for oral, ophthalmic or intravaginal use.
The exact strengths and the dosing figures are in the table above, taken from each label.
The warnings sit in different places, and counting them misleads
Isotretinoin carries a boxed warning about embryo-fetal toxicity. Retin-A Micro carries no boxed warning at all.
Look at the contraindications and you get the opposite impression: the Retin-A Micro label states that there are none, and the isotretinoin label lists only hypersensitivity to the product or its components. Read as a count, that makes the two look comparable. They are not, and this is a good illustration of why the number of entries in a section says nothing on its own. The pregnancy restriction that dominates isotretinoin sits in the boxed warning and in the indication itself, not in the contraindications list.
The reported side effects are local in one case and not in the other
The most common adverse reactions in the Retin-A Micro label are all at the site of application: skin irritation, burning, redness, peeling, dryness, itching and dermatitis. The isotretinoin list reaches well beyond the skin, adding back pain, joint pain, dry eye, nosebleeds, headache and nasopharyngitis alongside the dry lips and dry skin.
That difference follows from the route rather than from potency. A medicine swallowed reaches tissues a cream does not.
What this page does not tell you
It does not say which one a person should use, and the difference in approved severity is not an invitation to self-select. Isotretinoin prescribing in the United States is tied to a risk management program, and both products are decisions for a clinician who knows the person's history.
Common questions
- Are isotretinoin and tretinoin the same drug?
- They are different molecules, both retinoids and both derived from vitamin A, with separate FDA approvals. One is taken by mouth and one is applied to the skin, and their labels cover different severities of acne.
- Is the oral one stronger?
- The labels do not rank them, and they were not studied against each other. What the isotretinoin label does state is that it is reserved for severe nodular acne unresponsive to conventional therapy, which is a statement about where it sits in treatment rather than about strength.
- Retin-A Micro lists no contraindications. Does that make it safer?
- A short contraindications section is not a safety score. It means the label names no group for whom the product must not be used; warnings, precautions and adverse reactions are recorded in their own sections, and the full lists from both labels are reproduced on the individual pages.
Sources
Every fact above comes from one of these documents. The date is the effective date of the label version this page was built from.
FDA prescribing information for Isotretinoin capsules
Upsher-Smith Laboratories, LLC. Label version 4, effective 13 February 2026.
FDA prescribing information for Retin-A Micro
Bausch Health US LLC. Label version 23, effective 1 September 2025.
Each stripe is one section of the label, each division in a stripe one entry in that section. The red bar marks a boxed warning.
Other comparisons in this category
Page last updated 23 August 2026
Compiled by the HealthyStudy editorial team from FDA source documents. No medical reviewer is credited on this page, because none reviewed it.